CS/BSE/NSE/PR/2019-2020
April 03, 2019

To
The General Manager
Department of Corporate Services
BSE Limited
25th Floor, P. J. Towers,
Dalal Street, Mumbai - 400 001

To
The Manager
Listing Department
National Stock Exchange of India Limited
Exchange Plaza, Bandra Kurla Complex
Bandra (E), Mumbai – 400 051

Stock Code: 530239
Stock Code: SUVEN - EQ

Dear Sir/Madam,

Sub: Press Release

With reference to above subject, please find enclosed Press Release of our company titled “Suven Life Sciences secures Product Patents in Israel, Japan, New Zealand and Sri Lanka”.

This is for your information and record.

Thanking You,
Yours faithfully,
For Suven Life Sciences Limited

K. Hanumantha Rao
Company Secretary
News Release

Suven Life Sciences secures Product Patents in Israel, Japan, New Zealand and Sri Lanka

HYDERABAD, INDIA (April 03, 2019) – Suven Life Sciences Ltd (Suven) announces today that the grant of one (1) product patent from Israel (257869), one (1) product patent from Japan (6466602), one (1) product patent from New Zealand (737892) and one (1) product patent from Sri Lanka (16614) corresponding to the New Chemical Entities for the treatment of disorders associated with Neurodegenerative diseases and patents are valid through 2036 and 2029 respectively.

The granted claims of the patents include the class of selective 5-HT4 and M1 PAM compounds and are being developed as therapeutic agents for neurodegenerative disorders such as for the treatment of cognitive impairment associated with neurodegenerative disorders like Alzheimer’s disease, Attention deficient hyperactivity disorder (ADHD), Huntington’s disease, Pain, Parkinson Disease and Schizophrenia etc.

“We are very pleased by the grant of these patents to Suven for our pipeline of molecules in CNS arena that are being developed for cognitive disorders with high unmet medical need with huge market potential globally” says Venkat Jasti, CEO of Suven.

About Suven Life Sciences

Suven Life Science is a biopharmaceutical company focused on discovering, developing and commercializing novel pharmaceutical products, which are first in class or best in class CNS therapies using GPCR targets. Suven has 4 clinical stage compounds, a Phase 2 undergoing SUVN-502, Phase 2 ready SUVN-G3031, Phase 1 completed SUVN-D4010 and SUVN-911.

In addition to these clinical compounds the Company has nine (9) internally-discovered therapeutic drug candidates currently in various stages of pre-clinical development targeting conditions such as ADHD, dementia, depression, Huntington’s disease, Parkinson’s disease and pain.

For more information please visit our Web site at http://www.suven.com

Risk Statement:
Except for historical information, all of the statements, expectations and assumptions, including expectations and assumptions, contained in this news release may be forward-looking statements that involve a number of risks and uncertainties. Although Suven attempts to be accurate in making these forward-looking statements, it is possible that future circumstances might differ from the assumptions on which such statements are based. Other important factors which could cause results to differ materially including outsourcing trends, economic conditions, dependence on collaborative partnership programs, retention of key personnel, technological advances and continued success in growth of sales that may make our products/services offerings less competitive; Suven may not undertake to update any forward-looking statements that may be made from time to time.